http://www.asm.org/modules/mod_image_show_gk4/cache/Science Advisor Slidegk-is-651.jpglink
http://www.asm.org/modules/mod_image_show_gk4/cache/World AIDS Day Bannergk-is-651.pnglink
http://www.asm.org/modules/mod_image_show_gk4/cache/Amy Chang Bannergk-is-651.jpglink
http://www.asm.org/modules/mod_image_show_gk4/cache/2016.Kavli Slide Submitgk-is-651.jpglink
http://www.asm.org/modules/mod_image_show_gk4/cache/Governance Hero Bannergk-is-651.jpglink
0 1 2 3 4
Progress bar
04-12-2016Science Advisor
04-12-2016World AIDS Day
04-12-2016Amy Chang
04-12-2016Kavli Submit
04-12-2016Nominate
Become a member today!
JOIN/RENEW
Submit to an ASM Journal
SUBMIT
Antibacterial Development Conference
REGISTER

 

campadelli-fiume gabriellaDr. Campadelli Fiume's research focuses on the molecular basis of herpes simplex virus (HSV) entry into susceptible cells, and on engineering of candidate oncolytic HSVs retargeted to tumor-specific receptors. HSV entry is a multistep process. First, gD binds to one of its receptors and triggers virion-cell fusion. Fusion is executed by the conserved glycoproteins gH/gL and gB. Major accomplishments by the labs were the discovery of nectin as HSV receptor, and the triggering activity of receptor-bound gD, including the identification of gD profusion domain. Current aims include identification of the role of gH/gL in fusion. Starting from this background we have modified gD and re-addressed this molecule to the tumor-specific receptor HER-2. She has provided the first proof of principle evidence that retargeted HSVs exert antitumor activity in vivo.

TPL_asm2013_SEARCH

91007